Roland B Walter MD PhD MS

PubMed

• Predictors of Cardiac Recovery in Adults With AML Who Develop Heart Failure During Treatment.
  Matthew Wu, Kathryn Russell, Carole M Shaw, Anna B Halpern, Cristina Ghiuzeli
  JCO Oncology Practice. 2025-04-03
• 1 citations
  Relationship between age, conditioning intensity, and outcome after allografting in adults age ≥60 years with AML.
  Phuong T Vo, Brenda M Sandmaier, Megan Othus, Naveed Ali, Eduardo Rodríguez-Arbolí
  Bone Marrow Transplantation. 2025-04-01
• Preclinical characterization of the anti-leukemia activity of the CD123 antibody-drug conjugate, pivekimab sunirine (IMGN632).
  Frances M Cole, George S Laszlo, Margaret C Lunn-Halbert, Allie R Kehret, Patrick A Zweidler-McKay
  Leukemia. 2025-03-21

Journal Articles

• Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, Mitoxantrone, and G-CSF with Dose-Escalated Mitoxantrone for relapsed/refractory Acute Myeloid Leukemia or Other H...  
  Kelda M Gardner, Vivian G Oehler, Heather A Smith, Anna B Halpern, Paul C Hendrie, Sarah A Buckley, Roland B Walter, Pamela S Becker, Ryan D Cassaday, Asma Anwar, Bart..., Haematologica
• Second Cycle Remission Achievement with 7+3 and Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials  
  Brent L Wood, Roland B Walter, John E Godwin, James K Weick, Elihu H Estey, Derek L Stirewalt, Frederick R Appelbaum, Nature
• Relationship Between CD33 Expression, Splicing Polymorphism, and in Vitro Cytotoxicity of Gemtuzumab Ozogamicin and the CD33/CD3 BiTErAMG 330  
  Colin D Godwin, Roland B Walter, Haematologica
• A Phase 1 Trial of Vadastuximab Talirine Combined with Hypomethylating Agents in Patients with CD33 Positive AML  
  Eytan M Stein, Anand Jillella, Anthony S Stein, Amir T Fathi, Roland B Walter, Jeffrey E Lancet, Tibor J Kovacsovics, Anjali S Advani, Phoenix A Ho, Dale Bixby, Blood
• Join now to see all

Abstracts/Posters

• Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML)
  Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia
  Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart¬ Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
  Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myel...
  Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Treatment of Refractory Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome: Implications of Further Care at an Academic Center Versus Community Setting
  Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Anti-Apoptotic BCL-2 Family Members Confer Resistance to Calicheamicin-Based Antibody-Drug Conjugate Therapy of Acute Leukemia
  Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Frequency, and Effect on Survival, of Ineligibility for Clinical Trials in Newly Diagnosed Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
  Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• CRISPR/Cas9-Mediated Protection of Normal Hematopoiesis Combined with the CD33/CD3 Bispecific T-Cell Engager (BiTE) Antibody AMG330 for Improved AML Therapy
  Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Comparison of Acute Myeloid Leukemia Measurable Residual Disease Detection By Flow Cytometry in Peripheral Blood and Bone Marrow
  Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) ...
  Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Treatment Decision Making in AML: Factors of Importance to Clinicians, AML Patients and Their Family
  Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia
  Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions
  Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Mini- Vs. Regular-Dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less Fit Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and Othe...
  Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Myelodysplastic Syndrome with Excess Blasts and Secondary Acute Myeloid Leukemia: Same Disease with Different Blast Count
  Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leu...
  Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (A...
  Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE¬ (Bispecific T-Cell Engager) in Patients with R...
  Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) ...
  Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• COVA4231, a Potent CD3/CD33 Bispecific FynomAb with IgG-like Pharmacokinetics for the Treatment of Acute Myeloid Leukemia
  Roland Walter, MD, Nature, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Treating Acute Myeloid Leukemia: Case Challenges and Emerging Therapies 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Addition of Crenolanib to Induction Chemotherapy Overcomes the Poor Prognostic Impact of Co- Occurring Driver Mutations in Patients with Newly Diagnosed FLT3-Mutated AML 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Engineering Resistance to CD33-Targeted Immunotherapy in Normal Hematopoiesis By CRISPR/Cas9-Deletion of CD33 Exon 2 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Predicting Induction Toxicity with 7+3: Analysis of SWOG Trial S1203 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Novel Therapies for AML: Expanding Future Options 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Join now to see all